<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">CTJ</journal-id>
<journal-id journal-id-type="hwp">spctj</journal-id>
<journal-id journal-id-type="nlm-ta">Clin Trials</journal-id>
<journal-title>Clinical Trials</journal-title>
<issn pub-type="ppub">1740-7745</issn>
<issn pub-type="epub">1740-7753</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1740774512470766</article-id>
<article-id pub-id-type="publisher-id">10.1177_1740774512470766</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Author’s response</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Small-sample behavior of novel phase I designs: Rejoinder</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Oron</surname><given-names>Assaf P</given-names></name>
<xref ref-type="aff" rid="aff1-1740774512470766">a</xref>
<xref ref-type="aff" rid="aff2-1740774512470766">b</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Hoff</surname><given-names>Peter D</given-names></name>
<xref ref-type="aff" rid="aff3-1740774512470766">c</xref>
</contrib>
</contrib-group>
<aff id="aff1-1740774512470766"><label>a</label>Core for Biomedical Statistics, Seattle Children’s Research Institute, Seattle, WA, USA</aff>
<aff id="aff2-1740774512470766"><label>b</label>Professional and Continuing Education, University of Washington, Seattle, WA, USA</aff>
<aff id="aff3-1740774512470766"><label>c</label>Departments of Statistics and Biostatistics, University of Washington, Seattle, WA, USA</aff>
<author-notes>
<corresp id="corresp1-1740774512470766">Assaf P Oron, Core for Biomedical Statistics, Seattle Children’s Research Institute, 2001 Eighth Avenue, Suite 500, Seattle, WA 98121, USA. Email: <email>assaf.oron@seattlechildrens.org</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>2</month>
<year>2013</year>
</pub-date>
<volume>10</volume>
<issue>1</issue>
<fpage>88</fpage>
<lpage>92</lpage>
<permissions>
<copyright-statement>© The Author(s), 2013</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="sage">The Society for Clinical Trials</copyright-holder>
</permissions>
</article-meta>
</front>
<body>
<p>We express our deepest thanks to the reviewers and commenters for their commitment and passion regarding Phase I trial design. Our main goal has been to highlight some of the less studied aspects of novel Long-Memory Phase I designs, in particular (1) their core ‘engine’ or operating principle, as described in the ‘Long-memory designs operating principle’ section; (2) their tendency to ‘settle’, its causes, and its implications; and (3) various side effects related to the operational complexity of Bayesian designs such as continual reassessment method (CRM). By drawing attention to these characteristics, we hope to assist researchers in making informed decisions about the benefits, drawbacks, and limitations of various design choices.</p>
<p>While discussing statistical design properties, we should keep in mind the application toward which these designs are aimed. From our modest experience with Phase I and similar experiments, and from the general body of public knowledge, we believe that the top Phase I priorities for most clinicians and regulatory agencies are (roughly speaking) safety, reliability, and clarity. Statistical efficiency at finding an optimum point, while obviously important, is secondary to these concerns. This is a major reason why the outdated and inefficient ‘3 + 3’ protocol has had such a strong staying power in this field. Our task is to come up with designs that respect these priorities while improving statistical efficiency.</p>
<p>In our original layout for the article, Up-and-Down designs were only used as a simulation comparison, mostly in order to draw a contrast in properties, and also to show that there do exist full-fledged statistical dose-finding approaches that are neither Long-Memory nor Bayesian. From revision to revision, the space dedicated to Up-and-Down has expanded, in direct response to reviewer and editor requests. Not until the last version did the actual Up-and-Down transition rules appear.</p>
<p>As our article states, Up-and-Down has its own set of problems. It is not nearly as flexible as Long-Memory designs, and the efficiency of more flexible Up-and-Down variants is somewhat lower. Also, at present, the isotonic regression estimator’s confidence-interval options lack either in coverage or in sharpness. However, Up-and-Down remains a highly relevant and convenient benchmark to test novel methods against. We reiterate that on the single accepted Phase I efficiency metric, that is, maximum tolerated dose (MTD)-selection success rate (or, equivalently, estimation error), Up-and-Down performs on par with the leading Long-Memory designs, despite the far heavier investment of method-development resources in the latter, not to mention their complexity. The challenge, therefore, is to come up with a novel design that provides a clear performance edge over Up-and-Down, while not costing too much in other tangibles, first and foremost safety, reliability, and clarity.</p>
<sec id="section1-1740774512470766">
<title>Response to Carlin, Zhong, and Koopermeiners</title>
<p>We thank Carlin <italic>et al</italic>. for their thoughtful comments. We find ourselves in agreement with them on most points. In particular, we see their suggested novel design (the details of which we lack the time and space to discuss here) as another hybrid design, like the ones suggested by Oron [<xref ref-type="bibr" rid="bibr1-1740774512470766">1</xref>] or by Resche-Rigon <italic>et al</italic>. [<xref ref-type="bibr" rid="bibr2-1740774512470766">2</xref>], which it resembles more closely. We also agree with Carlin <italic>et al</italic>. that the performance of Bayesian models is related to the viability of their shot at approximating reality. As written in the article’s ‘Discussion’ section, a properly Bayesian approach to Phase I should include a realistic model, and a decision rule geared to optimize some trade-off between information-collection and safety.</p>
<p>However, the model of one-parameter CRM – by far the most widely used and discussed Bayesian Long-Memory design – is <italic>not</italic> intended as such a realistic approximation, but rather as a ‘working model’. It is therefore not a coincidence that the nonparametric, non-Bayesian cumulative cohort design (CCD), whose ‘model’ is a rudimentary estimate of the toxicity rate <inline-formula id="inline-formula1-1740774512470766"><mml:math display="inline" id="math1-1740774512470766"><mml:mrow><mml:mover><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mo>^</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula> at the current dose, exhibits small-sample and asymptotic behavior very similar to CRM’s. This is because CRM itself, just like CCD, really only relies upon the dose–response monotonicity and upon an <inline-formula id="inline-formula2-1740774512470766"><mml:math display="inline" id="math2-1740774512470766"><mml:mrow><mml:mover><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mo>^</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>-based likelihood as indispensable assumptions (see again the article’s ‘Long-memory designs operating principle’ section). CRM’s remaining Bayesian minutiae – model specification, prior, and so on – are all engineered to provide a desired ‘feel’ to the design’s experimental trajectories, or – using recent advanced tools [<xref ref-type="bibr" rid="bibr3-1740774512470766">3</xref>] – to indirectly calibrate the convergence interval’s width. In short, at present, a Bayesian discussion of the merits and pitfalls of designs such as CRM is moot because they are not Bayesian in the strict sense, as such a discussion requires.</p>
<p>In the same vein, we would like to reiterate that we do not object in principle to using the likelihood itself, or Bayesian methods per se, for Phase I. It is the combination of likelihood estimation and winner-take-all transition rules that generates what Carlin <italic>et al</italic>. call ‘sticky’ dose assignment patterns, and we call ‘settling’. Simply put, the degree of uncertainty in <inline-formula id="inline-formula3-1740774512470766"><mml:math display="inline" id="math3-1740774512470766"><mml:mrow><mml:mover><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mo>^</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula> for typical Phase I sample sizes does not justify a winner-take-all approach, and one inevitably pays a price for ignoring this basic probabilistic fact. Is there a way to implement likelihood estimation into Phase I designs in a more judicious manner, while respecting safety, reliability, and clarity? This is the challenge.</p>
<p>And here is where we differ somewhat from Carlin <italic>et al</italic>. We find no reason to call some designs ‘ad hoc’ or even a ‘retreat’, just because they do not use the likelihood for dose allocation. Placing an arbitrary memory-length cutoff on the likelihood, as Carlin <italic>et al</italic>. do in their suggested design, is arguably just as ad hoc as any Up-and-Down transition rule. To go a step further, in reality, Phase I study participants are volunteers with difficult prognoses, and often with widely divergent patterns of complications and additional conditions. We impose upon this study population a random-sampling model and a cumulative distribution function (CDF) called <italic>F</italic>, out of statistical convenience: it enables us to examine design and estimator properties. But this imposition is ad hoc in itself. In a way, Up-and-Down is more adequate than sophisticated parametric approaches that place too much store in the fiction that is <italic>F</italic>. Moreover, as far as theoretical <italic>properties</italic> are concerned, Up-and-Down is the least ad hoc among existing Phase I designs because its properties are the most tractable and the best understood. Interestingly, Carlin <italic>et al</italic>. contemplate a Bayesian design that would sample from the posterior MTD distribution. But this feat is already achieved by Up-and-Down: once the starting-point effect wears off (and this occurs fairly rapidly), the random-walk samples from a distribution with known properties, sharply peaked near the true MTD.</p>
<p>This brings us to our last and possibly most important disagreement with Carlin <italic>et al</italic>. They suggest that events such as the complete redesign that Neuenschwander <italic>et al</italic>.’s [<xref ref-type="bibr" rid="bibr4-1740774512470766">4</xref>] study went through mid-experiment, are a demonstration of the advantages of Bayesian methods and their flexibility. Even as statisticians, we take issue with this claim because the process seems rather post hoc, and designed toproduce a preconceived data-driven outcome (namely, de-escalate after the observed double-toxicity cohort, rather than escalate as the original design had decided). But our concerns probably pale in comparison to what most Data and Safety Monitoring Boards (DSMBs), Data Monitoring Committees (DMCs), and regulators would say when encountered with such a proposal, to completely revamp the design mid-stream because the previous design had failed. While it is up to the authorities to decide how to triage a specific experiment, statisticians usually pride themselves on taking the conservative, ‘gatekeeper of science’ side of such discussions. We do not find it desirable to grant ourselves a blanket exemption from this role when it comes to Phase I studies.</p>
</sec>
<sec id="section2-1740774512470766">
<title>Response to Cheung</title>
<p>We thank Y. K. Cheung for joining the discussion and contributing thoughtful comments, and for very concisely summarizing three of our main points. We have great respect for Cheung’s theoretical and practical contribution to Phase I designs. As with Carlin <italic>et al</italic>., we agree with many of Cheung’s observations. Some of his comments have challenged us to revisit and expand our simulation; selected results are in the following.</p>
<p>Perhaps our most salient disagreement with Cheung is the contrast between Long-Memory convergence and ‘settling’. Cheung explains our evidence that the two are different (most clearly demonstrated in the article’s Figure 8) by reminding readers that CRM is not guaranteed to converge to the MTD under all scenarios. But in four of the scenarios depicted in Figure 8, the Cheung–Chappell conditions for convergence to the MTD are met, and hence, had the simulation been run indefinitely, all runs would have ended with repeated identical allocations to the true MTD [<xref ref-type="bibr" rid="bibr5-1740774512470766">5</xref>].<sup><xref ref-type="fn" rid="fn1-1740774512470766">*</xref></sup> Figure 8 shows that the first instance of ‘settling’, defined there as five consecutive identical allocations, takes place rather often at non-MTD dose levels. Revisiting the random-<italic>F</italic> simulations discussed in the section ‘Simulations with random <italic>F</italic>’, among runs guaranteed to converge to the true MTD, the success rate of five-cohort ‘settling’ in predicting the MTD is only 45%.</p>
<p>What is so confusing about this is that ‘settling’ mimics CRM’s asymptotic behavior, namely, repeated allocation of the same dose level.<sup><xref ref-type="fn" rid="fn2-1740774512470766">†</xref></sup> Practically speaking, one could argue that the difference is only a matter of quantity rather than quality. Had we defined ‘settling’ as 50 repeated allocations to the same dose rather than 5, it would have produced far better results. As an example, we simulated runs of length <italic>n</italic> = 200, for 500 randomly selected runs with <inline-formula id="inline-formula4-1740774512470766"><mml:math display="inline" id="math4-1740774512470766"><mml:mrow><mml:mi>l</mml:mi><mml:mo>=</mml:mo><mml:mn>7</mml:mn></mml:mrow></mml:math></inline-formula> dose levels from the random-<italic>F</italic> ensemble. Among the runs in which CRM converges to the true MTD, 85% of the ‘settling’ runs ‘settled’ correctly when the criterion was 50 consecutive cohorts. If we were to run a simulation examining 500-cohort ‘settling’, the success rate would doubtlessly approach unity.</p>
<p>Unfortunately, we do not have hundreds of patients for each Phase I trial. As written in the article, all Long-Memory convergence proofs rely upon the convergence of the <inline-formula id="inline-formula5-1740774512470766"><mml:math display="inline" id="math5-1740774512470766"><mml:mrow><mml:mover><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mo>^</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>, that is, at best only as fast as binomial proportions [<xref ref-type="bibr" rid="bibr6-1740774512470766">6</xref>]. The ‘settling’ observed during the experiment is not evidence for convergence – neither to the MTD nor to a tolerance interval. Rather, it is a <italic>structural</italic> side effect of the interplay between a discrete dose set, a likelihood-based optimization and a winner-take-all dose assignment rule: once the incremental changes to the likelihood become too small to shift the balance between <inline-formula id="inline-formula6-1740774512470766"><mml:math display="inline" id="math6-1740774512470766"><mml:mrow><mml:mover><mml:mrow><mml:mi>MTD</mml:mi></mml:mrow><mml:mo stretchy="true">^</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula> and its neighbors, ‘settling’ begins to dominate. In our view, this is an undesirable property, and future methodological work should eliminate or mitigate it.</p>
<p>Cheung raises a valid concern with respect to Up-and-Down and toxic responses. Wouldn’t a random walk keep returning, well, <italic>randomly</italic>, to high doses that have already been flagged as dangerous? Of course, Up-and-Down generates experimental trajectories quite different from Long-Memory’s ‘settling’ prone ones. However, Up-and-Down theory indicates that the asymptotic visit frequency sharply drops away from the mode of the random-walk distribution, in a faster-than-exponential rate [<xref ref-type="bibr" rid="bibr7-1740774512470766">7</xref>]. This means that with 6–7 dose levels or more, visits to doses higher than one level above the MTD are quite rare. Specifically, Cheung asked how often would Up-and-Down designs produce visits to levels with <inline-formula id="inline-formula7-1740774512470766"><mml:math display="inline" id="math7-1740774512470766"><mml:mrow><mml:mi>F</mml:mi><mml:mo>&gt;</mml:mo><mml:mn>0</mml:mn><mml:mo>.</mml:mo><mml:mn>5</mml:mn></mml:mrow></mml:math></inline-formula>. The table on the next page presents the answer for the same data set used in our random-<italic>F</italic> simluation (the article’s Table 3). All numbers are counts of runs.</p>
<p>With <inline-formula id="inline-formula8-1740774512470766"><mml:math display="inline" id="math8-1740774512470766"><mml:mrow><mml:mi>l</mml:mi><mml:mo>=</mml:mo><mml:mn>7</mml:mn></mml:mrow></mml:math></inline-formula>, Up-and-Down’s score on this safety metric is somewhat better than either of the Long-Memory designs.<sup><xref ref-type="fn" rid="fn3-1740774512470766">‡</xref></sup> The transition rules prevent the assignment of the majority of patients to dangerously toxic levels, whereas with Long-Memory this unfortunate outcome might occur albeit rarely (bottom two rows). Observing more than two visits to such levels in any given 25-patient run is also less prevalent under Up-and-Down, compared with the Long-Memory designs (3.4% compared with 3.8% for CRM and 5.1% for CCD). With <inline-formula id="inline-formula9-1740774512470766"><mml:math display="inline" id="math9-1740774512470766"><mml:mrow><mml:mi>l</mml:mi><mml:mo>=</mml:mo><mml:mn>4</mml:mn></mml:mrow></mml:math></inline-formula>, Up-and-Down’s safety performance somewhat deteriorates, as expected, since the asymptotic visit peak is not as well defined. Conversely, Long-Memory’s safety performance somewhat improves since discriminating between adjacent doses based on <inline-formula id="inline-formula10-1740774512470766"><mml:math display="inline" id="math10-1740774512470766"><mml:mrow><mml:mover><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mo>^</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula> becomes easier with fewer dose levels. Even with <inline-formula id="inline-formula11-1740774512470766"><mml:math display="inline" id="math11-1740774512470766"><mml:mrow><mml:mi>l</mml:mi><mml:mo>=</mml:mo><mml:mn>4</mml:mn></mml:mrow></mml:math></inline-formula>, Up-and-Down rates are not egregiously higher (4.6% of Up-and-Down runs had more than two <inline-formula id="inline-formula12-1740774512470766"><mml:math display="inline" id="math12-1740774512470766"><mml:mrow><mml:mi>F</mml:mi><mml:mo>&gt;</mml:mo><mml:mn>0</mml:mn><mml:mo>.</mml:mo><mml:mn>5</mml:mn></mml:mrow></mml:math></inline-formula> visits, vs. 1.9% for CRM and 4.2% for CCD). And this can be mitigated via a priori protocol modifications. Just as many CRM protocols impose a second safety rule besides the main dose-allocation rule, preventing escalation to levels flagged as probably too toxic, similar modifications can be made to Up-and-Down-based protocols regarding repeat visits to a level whose earlier data yielded too many toxicities.</p>
<p>Cheung also suggests our chosen CRM skeletons might have tolerance intervals that are too wide, hurting performance. We ran the random-<italic>F</italic> simulations using three additional skeletons: two with an interval half-width of <inline-formula id="inline-formula13-1740774512470766"><mml:math display="inline" id="math13-1740774512470766"><mml:mrow><mml:mi>w</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mo>.</mml:mo><mml:mn>08</mml:mn></mml:mrow></mml:math></inline-formula>, as Cheung recommended (one with the prior-predictive <inline-formula id="inline-formula14-1740774512470766"><mml:math display="inline" id="math14-1740774512470766"><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>MTD</mml:mi></mml:mrow><mml:mo stretchy="true">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>4</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> and the other with <inline-formula id="inline-formula15-1740774512470766"><mml:math display="inline" id="math15-1740774512470766"><mml:mrow><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula>), and another one with a half-width of 0.06. The results are summarized in the second table on the next page. The original skeleton used in the article (table’s left-hand column) has a half-width of 0.116. The differences in performance are minor.</p>
<p>When discussing success metrics, Cheung writes that we ‘… consider the number <inline-formula id="inline-formula16-1740774512470766"><mml:math display="inline" id="math16-1740774512470766"><mml:mrow><mml:msup><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula> of cohorts treated at the MTD as a criterion …’. This is incorrect. In the ‘Introduction’, we wrote that high ensemble-average <inline-formula id="inline-formula17-1740774512470766"><mml:math display="inline" id="math17-1740774512470766"><mml:mrow><mml:msup><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula> values ‘… have been repeatedly invoked as a compelling reason for choosing’ Long-Memory. It is not us who had invoked them. Moreover, we doubt that most clinicians, on their own, would see <inline-formula id="inline-formula18-1740774512470766"><mml:math display="inline" id="math18-1740774512470766"><mml:mrow><mml:msup><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula> as equally important to safety, reliability, clarity, and MTD-selection success.</p>
<table-wrap id="table1-1740774512470766" position="float">
<graphic alternate-form-of="table1-1740774512470766" xlink:href="10.1177_1740774512470766-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Visits to <inline-formula id="inline-formula19-1740774512470766"><mml:math display="inline" id="math19-1740774512470766"><mml:mrow><mml:mi>F</mml:mi><mml:mo>&gt;</mml:mo><mml:mn>0</mml:mn><mml:mo>.</mml:mo><mml:mn>5</mml:mn></mml:mrow></mml:math></inline-formula> levels</th>
<th align="left" colspan="3">
<inline-formula id="inline-formula20-1740774512470766">
<mml:math display="inline" id="math20-1740774512470766">
<mml:mrow>
<mml:mi>l</mml:mi>
<mml:mo>=</mml:mo>
<mml:mn>7</mml:mn>
</mml:mrow>
</mml:math>
</inline-formula><hr/></th>
<th align="left" colspan="3">
<inline-formula id="inline-formula21-1740774512470766">
<mml:math display="inline" id="math21-1740774512470766">
<mml:mrow>
<mml:mi>l</mml:mi>
<mml:mo>=</mml:mo>
<mml:mn>4</mml:mn>
</mml:mrow>
</mml:math>
</inline-formula><hr/></th>
</tr>
<tr>
<th/>
<th align="left">CRM</th>
<th align="left">CCD</th>
<th align="left">U&amp;D</th>
<th align="left">CRM</th>
<th align="left">CCD</th>
<th align="left">U&amp;D</th>
</tr>
</thead>
<tbody>
<tr>
<td>None</td>
<td>1809</td>
<td>1763</td>
<td>1776</td>
<td>1864</td>
<td>1780</td>
<td>1664</td>
</tr>
<tr>
<td>1</td>
<td>100</td>
<td>84</td>
<td>98</td>
<td>85</td>
<td>95</td>
<td>160</td>
</tr>
<tr>
<td>2</td>
<td>16</td>
<td>51</td>
<td>59</td>
<td>13</td>
<td>41</td>
<td>85</td>
</tr>
<tr>
<td>3–4</td>
<td>36</td>
<td>48</td>
<td>39</td>
<td>16</td>
<td>41</td>
<td>58</td>
</tr>
<tr>
<td>5–9</td>
<td>26</td>
<td>32</td>
<td>28</td>
<td>15</td>
<td>26</td>
<td>31</td>
</tr>
<tr>
<td>10–19</td>
<td>10</td>
<td>16</td>
<td>0</td>
<td>6</td>
<td>12</td>
<td>2</td>
</tr>
<tr>
<td>20+</td>
<td>3</td>
<td>6</td>
<td>0</td>
<td>1</td>
<td>5</td>
<td>0</td>
</tr>
<tr>
<td>Total</td>
<td>2000</td>
<td>2000</td>
<td>2000</td>
<td>2000</td>
<td>2000</td>
<td>2000</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1740774512470766">
<p>CRM: continual reassessment method; CCD: cumulative cohort design; U&amp;D: Up-and-Down.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table2-1740774512470766" position="float">
<graphic alternate-form-of="table2-1740774512470766" xlink:href="10.1177_1740774512470766-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Outcome</th>
<th align="left">
<inline-formula id="inline-formula22-1740774512470766">
<mml:math display="inline" id="math22-1740774512470766">
<mml:mrow>
<mml:mn>0</mml:mn>
<mml:mo>.</mml:mo>
<mml:mn>116</mml:mn>
<mml:mo>,</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>d</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>4</mml:mn>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:math>
</inline-formula>
</th>
<th align="left">
<inline-formula id="inline-formula23-1740774512470766">
<mml:math display="inline" id="math23-1740774512470766">
<mml:mrow>
<mml:mn>0</mml:mn>
<mml:mo>.</mml:mo>
<mml:mn>08</mml:mn>
<mml:mo>,</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>d</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>4</mml:mn>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:math>
</inline-formula>
</th>
<th align="left">
<inline-formula id="inline-formula24-1740774512470766">
<mml:math display="inline" id="math24-1740774512470766">
<mml:mrow>
<mml:mn>0</mml:mn>
<mml:mo>.</mml:mo>
<mml:mn>08</mml:mn>
<mml:mo>,</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>d</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>3</mml:mn>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:math>
</inline-formula>
</th>
<th align="left">
<inline-formula id="inline-formula25-1740774512470766">
<mml:math display="inline" id="math25-1740774512470766">
<mml:mrow>
<mml:mn>0</mml:mn>
<mml:mo>.</mml:mo>
<mml:mn>06</mml:mn>
<mml:mo>,</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>d</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>4</mml:mn>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:math>
</inline-formula>
</th>
</tr>
</thead>
<tbody>
<tr>
<td>MTD-selection success</td>
<td>
<inline-formula id="inline-formula26-1740774512470766">
<mml:math display="inline" id="math26-1740774512470766">
<mml:mrow>
<mml:mn>53</mml:mn>
<mml:mo>.</mml:mo>
<mml:mn>0</mml:mn>
</mml:mrow>
</mml:math>
</inline-formula>
</td>
<td>
<inline-formula id="inline-formula27-1740774512470766">
<mml:math display="inline" id="math27-1740774512470766">
<mml:mrow>
<mml:mn>53</mml:mn>
<mml:mo>.</mml:mo>
<mml:mn>0</mml:mn>
</mml:mrow>
</mml:math>
</inline-formula>
</td>
<td>
<inline-formula id="inline-formula28-1740774512470766">
<mml:math display="inline" id="math28-1740774512470766">
<mml:mrow>
<mml:mn>51</mml:mn>
<mml:mo>.</mml:mo>
<mml:mn>8</mml:mn>
</mml:mrow>
</mml:math>
</inline-formula>
</td>
<td>
<inline-formula id="inline-formula29-1740774512470766">
<mml:math display="inline" id="math29-1740774512470766">
<mml:mrow>
<mml:mn>54</mml:mn>
<mml:mo>.</mml:mo>
<mml:mn>2</mml:mn>
</mml:mrow>
</mml:math>
</inline-formula>
</td>
</tr>
<tr>
<td>High-<inline-formula id="inline-formula30-1740774512470766"><mml:math display="inline" id="math30-1740774512470766"><mml:mrow><mml:msup><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula> runs</td>
<td>
<inline-formula id="inline-formula31-1740774512470766">
<mml:math display="inline" id="math31-1740774512470766">
<mml:mrow>
<mml:mn>43</mml:mn>
<mml:mo>.</mml:mo>
<mml:mn>3</mml:mn>
</mml:mrow>
</mml:math>
</inline-formula>
</td>
<td>
<inline-formula id="inline-formula32-1740774512470766">
<mml:math display="inline" id="math32-1740774512470766">
<mml:mrow>
<mml:mn>43</mml:mn>
<mml:mo>.</mml:mo>
<mml:mn>7</mml:mn>
</mml:mrow>
</mml:math>
</inline-formula>
</td>
<td>
<inline-formula id="inline-formula33-1740774512470766">
<mml:math display="inline" id="math33-1740774512470766">
<mml:mrow>
<mml:mn>42</mml:mn>
<mml:mo>.</mml:mo>
<mml:mn>7</mml:mn>
</mml:mrow>
</mml:math>
</inline-formula>
</td>
<td>
<inline-formula id="inline-formula34-1740774512470766">
<mml:math display="inline" id="math34-1740774512470766">
<mml:mrow>
<mml:mn>40</mml:mn>
<mml:mo>.</mml:mo>
<mml:mn>7</mml:mn>
</mml:mrow>
</mml:math>
</inline-formula>
</td>
</tr>
<tr>
<td>Low-<inline-formula id="inline-formula35-1740774512470766"><mml:math display="inline" id="math35-1740774512470766"><mml:mrow><mml:msup><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula> runs</td>
<td>
<inline-formula id="inline-formula36-1740774512470766">
<mml:math display="inline" id="math36-1740774512470766">
<mml:mrow>
<mml:mn>29</mml:mn>
<mml:mo>.</mml:mo>
<mml:mn>4</mml:mn>
</mml:mrow>
</mml:math>
</inline-formula>
</td>
<td>
<inline-formula id="inline-formula37-1740774512470766">
<mml:math display="inline" id="math37-1740774512470766">
<mml:mrow>
<mml:mn>29</mml:mn>
<mml:mo>.</mml:mo>
<mml:mn>2</mml:mn>
</mml:mrow>
</mml:math>
</inline-formula>
</td>
<td>
<inline-formula id="inline-formula38-1740774512470766">
<mml:math display="inline" id="math38-1740774512470766">
<mml:mrow>
<mml:mn>29</mml:mn>
<mml:mo>.</mml:mo>
<mml:mn>8</mml:mn>
</mml:mrow>
</mml:math>
</inline-formula>
</td>
<td>
<inline-formula id="inline-formula39-1740774512470766">
<mml:math display="inline" id="math39-1740774512470766">
<mml:mrow>
<mml:mn>23</mml:mn>
<mml:mo>.</mml:mo>
<mml:mn>8</mml:mn>
</mml:mrow>
</mml:math>
</inline-formula>
</td>
</tr>
<tr>
<td>High-toxicity runs</td>
<td>
<inline-formula id="inline-formula40-1740774512470766">
<mml:math display="inline" id="math40-1740774512470766">
<mml:mrow>
<mml:mn>5</mml:mn>
<mml:mo>.</mml:mo>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:math>
</inline-formula>
</td>
<td>
<inline-formula id="inline-formula41-1740774512470766">
<mml:math display="inline" id="math41-1740774512470766">
<mml:mrow>
<mml:mn>7</mml:mn>
<mml:mo>.</mml:mo>
<mml:mn>3</mml:mn>
</mml:mrow>
</mml:math>
</inline-formula>
</td>
<td>
<inline-formula id="inline-formula42-1740774512470766">
<mml:math display="inline" id="math42-1740774512470766">
<mml:mrow>
<mml:mn>5</mml:mn>
<mml:mo>.</mml:mo>
<mml:mn>8</mml:mn>
</mml:mrow>
</mml:math>
</inline-formula>
</td>
<td>
<inline-formula id="inline-formula43-1740774512470766">
<mml:math display="inline" id="math43-1740774512470766">
<mml:mrow>
<mml:mn>5</mml:mn>
<mml:mo>.</mml:mo>
<mml:mn>3</mml:mn>
</mml:mrow>
</mml:math>
</inline-formula>
</td>
</tr>
<tr>
<td>Runs with ‘incoherence’</td>
<td>
<inline-formula id="inline-formula44-1740774512470766">
<mml:math display="inline" id="math44-1740774512470766">
<mml:mrow>
<mml:mn>0</mml:mn>
<mml:mo>.</mml:mo>
<mml:mn>0</mml:mn>
</mml:mrow>
</mml:math>
</inline-formula>
</td>
<td>
<inline-formula id="inline-formula45-1740774512470766">
<mml:math display="inline" id="math45-1740774512470766">
<mml:mrow>
<mml:mn>0</mml:mn>
<mml:mo>.</mml:mo>
<mml:mn>0</mml:mn>
</mml:mrow>
</mml:math>
</inline-formula>
</td>
<td>
<inline-formula id="inline-formula46-1740774512470766">
<mml:math display="inline" id="math46-1740774512470766">
<mml:mrow>
<mml:mn>0</mml:mn>
<mml:mo>.</mml:mo>
<mml:mn>2</mml:mn>
</mml:mrow>
</mml:math>
</inline-formula>
</td>
<td>
<inline-formula id="inline-formula47-1740774512470766">
<mml:math display="inline" id="math47-1740774512470766">
<mml:mrow>
<mml:mn>0</mml:mn>
<mml:mo>.</mml:mo>
<mml:mn>0</mml:mn>
</mml:mrow>
</mml:math>
</inline-formula>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-1740774512470766">
<p>MTD: maximum tolerated dose.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Our reading of the Phase I methodological literature suggests that developers and proponents of CRM, escalation with overdose control (EWOC), and other Long-Memory designs are the ones who have elevated <inline-formula id="inline-formula48-1740774512470766"><mml:math display="inline" id="math48-1740774512470766"><mml:mrow><mml:mover><mml:mrow><mml:msup><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msup></mml:mrow><mml:mo stretchy="true">¯</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>’s importance, because this is a metric on which the contrast between Long-Memory and other approaches is most stark [<xref ref-type="bibr" rid="bibr8-1740774512470766">8</xref>]. Our article shows that the Long-Memory increase in <inline-formula id="inline-formula49-1740774512470766"><mml:math display="inline" id="math49-1740774512470766"><mml:mrow><mml:mover><mml:mrow><mml:msup><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msup></mml:mrow><mml:mo stretchy="true">¯</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula> is a byproduct of the ‘settling’ phenomenon, meaning that it is achieved at the price of increasing variability and a host of other side effects. More fundamentally, with respect to <inline-formula id="inline-formula50-1740774512470766"><mml:math display="inline" id="math50-1740774512470766"><mml:mrow><mml:msup><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula>, we believe that promising to treat most patients at the MTD, when the experiment’s goal is to find the MTD, and when prior information about <italic>F</italic> is scant, is somewhat self-contradictory. A more realistic promise (regardless of specific design choice) would be that most volunteers’ assigned doses are likely to be closer to the MTD than random chance, but one cannot assure participants how close they will actually be.</p>
<p>We end with a discussion of complexity. Besides his theoretical and methodological contributions, Y.K. Cheung has done perhaps more than anyone else to make CRM design and analysis more practicable and approachable to nonspecialists. In his comment, Cheung graciously admits that despite these outreach efforts, planning a CRM trial remains a complex task but argues that complexity should not be the determining factor. We agree, and we suggest that the design-choice decision is related to the following three questions: (1) Is the complexity justified by the tangible benefits it delivers? (2) Assuming that the answer is ‘yes’, is the complexity mostly confined to the planning stage, as Cheung suggests – or does it spill over to the experiment itself? and (3) When in trouble, is there a solid body of comprehensive resources that would help clarify matters to the intrepid analyst?</p>
<p>Our article suggests that the first answer is ‘no’. But even if we accept a ‘sometimes’ (a resounding ‘yes’ is certainly not warranted by the evidence), it would be misguided to respond in the affirmative to the remaining two questions. Exhibit A is of course ‘settling’ and its side effects – a suite of phenomena unheeded by the Long-Memory design community. Even Cheung still does not quite accept that CRM converges slowly rather than quickly, and that small-sample ‘settling’ is a bug rather than a feature. Most other Long-Memory experts with whom we’ve had the fortune to converse have been even less accommodating.</p>
<p>‘Settling’ aside, the experimental mishaps detailed here and in the Web Supplement are largely the result of CRM’s superfluous complexity. Neuenschwander <italic>et al</italic>.’s experiment has served as verbal football for some time. Many have pointed out that the experiment was designed by CRM novices. But until now, the Mathew <italic>et al</italic>. 2004 study [<xref ref-type="bibr" rid="bibr9-1740774512470766">9</xref>], whose designer is an authority on CRM, has gone under the radar. The relationship between skeleton slope and trajectory volatility was apparently not noticed by the analyst prior to the experiment; otherwise, a less-volatile design might have been chosen. The model fit the observed patterns so poorly that despite <inline-formula id="inline-formula51-1740774512470766"><mml:math display="inline" id="math51-1740774512470766"><mml:mrow><mml:mover><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mo>^</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula> at the final dose being below the target toxicity rate (<inline-formula id="inline-formula52-1740774512470766"><mml:math display="inline" id="math52-1740774512470766"><mml:mrow><mml:mover><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mo>^</mml:mo></mml:mover><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mo>.</mml:mo><mml:mn>25</mml:mn></mml:mrow></mml:math></inline-formula> vs. <inline-formula id="inline-formula53-1740774512470766"><mml:math display="inline" id="math53-1740774512470766"><mml:mrow><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mo>.</mml:mo><mml:mn>3</mml:mn></mml:mrow></mml:math></inline-formula>), the model formally recommended the never-assigned dose below it as <inline-formula id="inline-formula54-1740774512470766"><mml:math display="inline" id="math54-1740774512470766"><mml:mrow><mml:mover><mml:mrow><mml:mi>MTD</mml:mi></mml:mrow><mml:mo stretchy="true">^</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>– a recommendation that, just like in the Neuenschwander <italic>et al</italic>. experiment, had to be overridden because it failed the common-sense test.</p>
<p>In another experiment published in 2008 and targeting <inline-formula id="inline-formula55-1740774512470766"><mml:math display="inline" id="math55-1740774512470766"><mml:mrow><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mo>.</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula>, an adverse response on the first subject dropped the assignment from <inline-formula id="inline-formula56-1740774512470766"><mml:math display="inline" id="math56-1740774512470766"><mml:mrow><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> to <inline-formula id="inline-formula57-1740774512470766"><mml:math display="inline" id="math57-1740774512470766"><mml:mrow><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula>, where it would have stayed stuck despite 13 consecutive benign responses had the experiment not terminated prematurely [<xref ref-type="bibr" rid="bibr2-1740774512470766">2</xref>]. The authors went on to develop a short/long-memory compromise design in order to mitigate such early and overbearing ‘settling’. Naturally, we have found this article interesting, but it took even us a third or fourth look at the data, to realize that the ’settling’ at <inline-formula id="inline-formula58-1740774512470766"><mml:math display="inline" id="math58-1740774512470766"><mml:mrow><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> was greatly exacerbated by that level’s skeleton value being a very low 0.001. If this value is changed to 0.01 (the <inline-formula id="inline-formula59-1740774512470766"><mml:math display="inline" id="math59-1740774512470766"><mml:mrow><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> value is 0.05), the length of stay at <inline-formula id="inline-formula60-1740774512470766"><mml:math display="inline" id="math60-1740774512470766"><mml:mrow><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> following the initial adverse response is shortened from 14 to 8 subjects.<sup><xref ref-type="fn" rid="fn4-1740774512470766">§</xref></sup> The senior author of that study is a leading, experienced, and widely respected CRM expert. Cheung’s design aid would have not helped in this case: whether it begins at 0.001 or 0.01, the skeleton produces the same asymptotic tolerance interval.</p>
<p>And these are only the published cases we are aware of. We have not carried out a thorough meta-analysis, so there might well be other published Long-Memory mishaps, as well as unpublished ones. We cannot evade the conclusion that CRM in its typical application, and probably also sibling designs such as EWOC, is too intractable and unwieldy even for us, the professionals tasked with crafting and steering a design through a life-or-death experiment.</p>
<p>Again, we hope that our article and the subsequent discussion will help the field provide better answers to researchers and analysts in need. Meanwhile, as the field turns toward adapting Long-Memory progeny to ever more complex tasks, such as toxicity-efficacy trials, multiagent trials, and so forth, it is perhaps a good idea to first stabilize a design with clear and known properties and solid performance for the basic single-endpoint, single-agent dose-finding problem.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="other" id="fn1-1740774512470766">
<label>*</label>
<p>In fact, two of the scenarios (Normal and Uniform) even meet the original, narrower Shen–O’Quigley conditions.</p>
</fn>
<fn fn-type="other" id="fn2-1740774512470766">
<label>†</label>
<p>In case the tolerance interval is too narrow, the asymptotic behavior might be oscillation between two adjacent levels.</p>
</fn>
<fn fn-type="other" id="fn3-1740774512470766">
<label>‡</label>
<p>With <inline-formula id="inline-formula61-1740774512470766"><mml:math display="inline" id="math61-1740774512470766"><mml:mrow><mml:mi>l</mml:mi><mml:mo>=</mml:mo><mml:mn>7</mml:mn></mml:mrow></mml:math></inline-formula>, Up-and-Down also had fewer runs with an overall high toxic response count; see Table 3.</p>
</fn>
<fn fn-type="other" id="fn4-1740774512470766">
<label>§</label>
<p>An analogous Up-and-Down design targeting <inline-formula id="inline-formula62-1740774512470766"><mml:math display="inline" id="math62-1740774512470766"><mml:mrow><mml:mi>p</mml:mi><mml:mo>≈</mml:mo><mml:mn>0</mml:mn><mml:mo>.</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula> would require six benign responses to re-escalate.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1740774512470766">
<label>1.</label>
<citation citation-type="web">
<person-group person-group-type="author">
<name><surname>Oron</surname><given-names>AP</given-names></name>
</person-group>. <source>Up-and-Down and the Percentile-Finding Problem</source>. <publisher-name>University of Washington</publisher-name>, <publisher-loc>Seattle, WA</publisher-loc>, <year>2007</year>. Available at: <ext-link ext-link-type="uri" xlink:href="http://arxiv.org/abs/0808.3004">http://arxiv.org/abs/0808.3004</ext-link></citation>
</ref>
<ref id="bibr2-1740774512470766">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Resche-Rigon</surname><given-names>M</given-names></name>
<name><surname>Zohar</surname><given-names>S</given-names></name>
<name><surname>Chevret</surname><given-names>S</given-names></name>
</person-group>. <article-title>Adaptive designs for dose-finding in non-cancer phase II trials: Influence of early unexpected outcomes</article-title>. <source>Clin Trials</source> <year>2008</year>; <volume>5</volume>: <fpage>595</fpage>–<lpage>606</lpage>.</citation>
</ref>
<ref id="bibr3-1740774512470766">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lee</surname><given-names>SM</given-names></name>
<name><surname>Cheung</surname><given-names>YK</given-names></name>
</person-group>. <article-title>Model calibration in the continual reassessment method</article-title>. <source>Clin Trials</source> <year>2009</year>; <volume>6</volume>: <fpage>227</fpage>–<lpage>38</lpage>.</citation>
</ref>
<ref id="bibr4-1740774512470766">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Neuenschwander</surname><given-names>B</given-names></name>
<name><surname>Branson</surname><given-names>M</given-names></name>
<name><surname>Gsponer</surname><given-names>T</given-names></name>
</person-group>. <article-title>Critical aspects of the Bayesian approach to phase I cancer trials</article-title>. <source>Stat Med</source> <year>2008</year>; <volume>27</volume>: <fpage>2420</fpage>–<lpage>39</lpage>.</citation>
</ref>
<ref id="bibr5-1740774512470766">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Azriel</surname><given-names>D</given-names></name>
</person-group>. <article-title>A note on the robustness of the continual reassessment method</article-title>. <source>Stat Probabil Lett</source> <year>2012</year>; <volume>82</volume>: <fpage>902</fpage>–<lpage>06</lpage>.</citation>
</ref>
<ref id="bibr6-1740774512470766">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Oron</surname><given-names>AP</given-names></name>
<name><surname>Azriel</surname><given-names>D</given-names></name>
<name><surname>Hoff</surname><given-names>PD</given-names></name>
</person-group>. <article-title>Dose-finding designs: The role of convergence properties</article-title>. <source>Int J Biostat</source> <year>2011</year>; <volume>7</volume>(<issue>1</issue>): Article <fpage>39</fpage>.</citation>
</ref>
<ref id="bibr7-1740774512470766">
<label>7.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Durham</surname><given-names>SD</given-names></name>
<name><surname>Flournoy</surname><given-names>N</given-names></name>
</person-group>. <article-title>Up-and-down designs. I Stationary treatment distributions</article-title>. In <person-group person-group-type="editor">
<name><surname>Flournoy</surname><given-names>N</given-names></name>
<name><surname>Rosenberger</surname><given-names>WF</given-names></name>
</person-group> (eds) <source>Adaptive Designs</source>, <volume>vol. 25</volume> of IMS Lecture Notes Monograph Series. <publisher-name>Institute of Mathematical Statistics</publisher-name>, <publisher-loc>Hayward, CA</publisher-loc>, <year>1995</year>, pp. <fpage>139</fpage>–<lpage>57</lpage>.</citation>
</ref>
<ref id="bibr8-1740774512470766">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rogatko</surname><given-names>A</given-names></name>
<name><surname>Schoeneck</surname><given-names>D</given-names></name>
<name><surname>Jonas</surname><given-names>W</given-names></name><etal/>
</person-group>. <article-title>Translation of innovative designs into phase I trials</article-title>. <source>J Clin Oncol</source> <year>2007</year>; <volume>25</volume>(<issue>31</issue>): <fpage>4982</fpage>–<lpage>86</lpage>.</citation>
</ref>
<ref id="bibr9-1740774512470766">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mathew</surname><given-names>P</given-names></name>
<name><surname>Thall</surname><given-names>PF</given-names></name>
<name><surname>Jones</surname><given-names>D</given-names></name><etal/>
</person-group>. <article-title>Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: A modular phase I trial in androgen-independent prostate cancer</article-title>. <source>J Clin Oncol</source> <year>2004</year>; <volume>22</volume>(<issue>16</issue>): <fpage>3323</fpage>–<lpage>29</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>